Drug Profile
Research programme: hepatocellular carcinoma therapeutics - Saronic Biotechnology
Latest Information Update: 18 Jul 2023
Price :
$50
*
At a glance
- Originator Saronic Biotechnology
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Liver cancer
Most Recent Events
- 18 Jul 2023 Hepatocellular carcinoma therapeutics are still in early research for Hepatocellular carcinoma in USA (Saronic Biotechnology pipeline, July 2023)
- 28 Apr 2020 No recent reports of development identified for research development in Liver-cancer in USA
- 15 Mar 2016 Early research in liver cancer in USA (unspecified route) before March 2016